Cabaletta Bio is trading 5.25% lower at $1.53, with broader inflation-related pressure a possible factor.

  • No company-specific announcement explaining the October 15 move surfaced; its latest listed company update was October 5, and a market source showed no October 15 headlines.
  • Reuters reported hotter-than-expected U.S. inflation raised rate-hike expectations and weighed on growth-sensitive stocks. This macro backdrop is plausible, not a confirmed company-specific catalyst.